

+ Evidence in focus

Publication summary: Regulski M, et al. OWM (2013)*

Smith+Nephew

Addition of GRAFIX[◇] Cryopreserved Placental Membrane to standard treatment helped the majority of chronic wounds to achieve complete closure within 12 weeks

+ Plus points

With use of GRAFIX Membrane plus standard treatment:




Overview

- Retrospective study conducted at a single outpatient wound care center in the USA in 66 patients with chronic wounds (N=67; average duration, 38 weeks; average size, 6.65cm²)
 - The majority of wounds were diabetic foot ulcers (DFUs; n=27) and venous leg ulcers (VLUs; n=34)
 - Of 66 patients, 74.6% had received prior advanced therapies (eg, skin grafts, cellular skin substitutes, collagen dressings)
- Patients received GRAFIX Membrane weekly in addition to standard care for up to 12 weeks or until complete wound closure, whichever was first
 - Standard care was regular sharp debridement, with offloading for DFUs and compression for VLUs
 - Complete closure was defined as 100% re-epithelialization with no evidence of drainage

Results

With use of GRAFIX Membrane plus standard treatment:

- 76.1% of wounds achieved complete closure within 12 weeks irrespective of baseline wound size (Figure)
 - Similar results were observed for VLUs and DFUs when analyzed separately (Figure)
- Average time to complete closure was 5.8 weeks using 3.2 GRAFIX Membrane applications
- 80.6% of wounds closed within 26 weeks without additional therapy beyond 12 weeks
- Of those with a duration >4 weeks to <6 months, 6 months to <2 years and ≥2 years, 77.8, 92.9 and 37.5% achieved complete closure, respectively
- The probability of complete closure of all wounds at 12 weeks was 82.6% with time to closure of 49 days (71.5% for VLUs; 89.7% for DFUs)



Conclusions

Addition of GRAFIX Membrane to standard treatment helped the majority of chronic wounds, including DFUs and VLUs, to achieve complete closure within 12 weeks.

Citation

*Regulski M, Jacobstein DA, Petranto RD, Migliori VJ, Nair G, Pfeiffer D. A retrospective analysis of a human cellular repair matrix for the treatment of chronic wounds. OWM. 2013;59(12):38–43.

Available from: [Ostomy Wound Management](#)

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.